Evidence map›Paper›PMID 39976819›Full record

ArticleClinical & experimental metastasis2025

Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2

Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, Alfonso Gómez de Liaño, Wataru Fukuokaya, Takahiro Kimura, Takafumi Yanagisawa, Patrizia Giannatempo, Martin Angel, Alessia Mennitto and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Ondřej Fiala *Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University Prague, Alej Svobody 80, 304 60, Pilsen, Czech Republic. fialao@fnplzen.cz.
Sebastiano Buti *Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Kazutoshi FujitaDepartment of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
Alfonso Gómez de LiañoDepartment of Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas, Spain.
Wataru FukuokayaDepartment of Urology, The Jikei University School of Medicine, 3-19-18 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, 3-19-18 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.
Takafumi YanagisawaDepartment of Urology, The Jikei University School of Medicine, 3-19-18 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.
Patrizia GiannatempoMedical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Giacomo Venezian 1, Milan, Italy.
Martin AngelClinical Oncology, Genitourinary Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina.
Alessia MennittoDepartment of Medical Oncology, Azienda Ospedaliera Universitaria "Maggiore Della Carit", Novara, Italy.
Javier Molina-CerrilloDepartment of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain.
Maria T BourlonDepartment of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Escuela de Medicina, Mexico-Universidad Panamericana, Mexico City, Mexico.
Andrey SoaresHospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Hideki TakeshitaDepartment of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Fabio CalabròMedical Oncology 1-IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Cinzia OrtegaDipartimento di Oncologia, Ospedale Michele E Pietro Ferrero-Verduno (CN) ASLCN2 Alba E, Bra, Italy.
Jakub KucharzDepartment of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland.
Michele MilellaSection of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University and Hospital Trust (AOUI) of Verona, 37134, Verona, Italy.
Emmanuel SerontDepartment of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Se Hoon ParkSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Deniz TuralDepartment of Medical Oncology, Koc University Medical Faculty, Istanbul, Türkiye.
Giovanni BenedettiU.O. Oncologia, Ospedale Di Civitanova Marche, Civitanova Marche, Italy.
Yüksel ÜrünDepartment of Medical Oncology, Ankara University Faculty of Medicine, 06620, Ankara, Türkiye.
Nicola BattelliMedical Oncology Unit, Macerata Hospital, Macerata, Italy.
Bohuslav MelicharDepartment of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
Alexandr PoprachDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic.
Tomas BuchlerDepartment of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, 150 06, Prague, Czech Republic.
Jindřich KopeckýDepartment of Oncology, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
Vincenza ConteducaUnit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy.
Fernando Sabino Marques MonteiroLatin American Cooperative Oncology Group-LACOG, Porto Alegre, Brazil.
Francesco MassariMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Shilpa Gupta *Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Matteo Santoni *Medical Oncology Unit, Macerata Hospital, Macerata, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with metastatic urothelial carcinoma (mUC) are typically elderly and often have other comorbidities that require the use of concomitant medications. In our study we evaluated the association of concomitant use of antibiotics (ATBs), proton pump inhibitors (PPIs), corticosteroids, statins, metformin and insulin with patient outcomes and we validated the prognostic role of a concomitant drug score in mUC patients treated with enfortumab vedotin (EV) monotherapy. Data from 436 patients enrolled in the ARON-2

Indexed as

Antibodies, MonoclonalCarcinoma, Transitional CellUrologic NeoplasmsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesAntibodies, Monoclonalenfortumab vedotinAntibioticsARON-2EV studyConcomitant drug scoreConcomitant medicationCorticosteroidsEnfortumab vedotinNCT05290038Urothelial cancer

Identifiers

PMID39976819
PMCPMC11842414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.